$INFU
InfuSystem Holdings, Inc Stock $infu

$infu Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000162828023008290 Filed on March 16, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$30.37M	$28.83M	$109.9M
YoY Change	13.48%	8.71%	7.36%
Cost Of Revenue	$14.83M	$12.75M	$47.34M
YoY Change	30.13%	13.74%	12.23%
Gross Profit	$15.54M	$16.08M	$62.57M
YoY Change	1.13%	5.03%	3.94%
Gross Profit Margin	51.17%	55.79%	56.93%
Selling, General & Admin	$15.29M	$14.69M	$58.34M
YoY Change	0.99%	17.37%	9.99%
% of Gross Profit	98.36%	91.31%	93.23%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.955M	$3.104M	$10.87M
YoY Change	9.2%	-15.1%	4.85%
% of Gross Profit	19.02%	19.3%	17.37%
Operating Expenses	$15.65M	$15.05M	$60.92M
YoY Change	-1.54%	9.8%	6.17%
Operating Profit	-$107.0K	$1.029M	$1.654M
YoY Change	-79.62%	-35.77%	-41.35%
Interest Expense	$484.0K	-$426.0K	$1.402M
YoY Change	74.73%	-8.97%	1.82%
% of Operating Profit		-41.4%	84.76%
Other Income/Expense, Net	-$35.00K	-$53.00K	-$122.0K
YoY Change	25.0%	47.22%	-34.41%
Pretax Income	-$626.0K	$550.0K	$130.0K
YoY Change	-24.58%	-49.91%	-89.66%
Income Tax	-$302.0K	$443.0K	$112.0K
% Of Pretax Income		80.55%	86.15%
Net Earnings	-$324.0K	$107.0K	$18.00K
YoY Change	-11.96%	-72.35%	-98.73%
Net Earnings / Revenue	-1.07%	0.37%	0.02%
Basic Earnings Per Share	-$0.02		$0.00
Diluted Earnings Per Share	-$0.02	$0.01	$0.00
COMMON SHARES
Basic Shares Outstanding	20.89M shares	20.66M shares	20.65M shares
Diluted Shares Outstanding	20.85M shares		21.55M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$256.0K	$165.0K	$165.0K
YoY Change	-36.79%	-11.29%	-11.29%
Cash & Equivalents	$256.0K	$165.0K	$165.0K
Short-Term Investments
Other Short-Term Assets	$3.752M	$2.922M	$2.922M
YoY Change	45.15%	15.27%	15.27%
Inventory	$5.644M	$4.821M	$4.821M
Prepaid Expenses
Receivables	$18.27M	$16.87M	$16.87M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.92M	$24.78M	$24.78M
YoY Change	20.03%	12.3%	12.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.391M	$4.385M	$50.79M
YoY Change	0.37%	-3.05%	0.83%
Goodwill	$3.710M	$3.710M
YoY Change	0.0%	0.0%
Intangibles	$8.188M	$8.436M
YoY Change	-19.87%	-22.82%
Long-Term Investments
YoY Change
Other Assets	$425.0K	$80.00K	$11.67M
YoY Change	-69.2%	-83.01%	11.1%
Total Long-Term Assets	$74.34M	$74.61M	$74.61M
YoY Change	-0.85%	-1.21%	-1.21%
TOTAL ASSETS
Total Short-Term Assets	$27.92M	$24.78M	$24.78M
Total Long-Term Assets	$74.34M	$74.61M	$74.61M
Total Assets	$102.3M	$99.39M	$99.39M
YoY Change	4.1%	1.85%	1.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.368M	$8.341M	$8.341M
YoY Change	-10.6%	6.09%	6.09%
Accrued Expenses			$892.0K
YoY Change			-10.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Total Short-Term Liabilities	$13.93M	$14.47M	$14.47M
YoY Change	-0.08%	12.18%	12.18%
LONG-TERM LIABILITIES
Long-Term Debt	$36.39M	$33.16M	$33.16M
YoY Change	4.58%	1.25%	1.25%
Other Long-Term Liabilities	$3.684M	$3.761M	$3.761M
YoY Change	6.75%	2.48%	2.48%
Total Long-Term Liabilities	$36.39M	$33.16M	$36.92M
YoY Change	4.58%	1.25%	1.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.93M	$14.47M	$14.47M
Total Long-Term Liabilities	$36.39M	$33.16M	$36.92M
Total Liabilities	$54.00M	$51.39M	$51.39M
YoY Change	3.48%	4.2%	4.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$59.82M	-$59.34M
YoY Change	2.65%	10.09%
Common Stock	$2.000K	$2.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.26M	$48.00M	$48.00M
YoY Change
Total Liabilities & Shareholders Equity	$102.3M	$99.39M	$99.39M
YoY Change	4.1%	1.85%	1.85%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$324.0K	$107.0K	$18.00K
YoY Change	-11.96%	-72.35%	-98.73%
Depreciation, Depletion And Amortization	$2.955M	$3.104M	$10.87M
YoY Change	9.2%	-15.1%	4.85%
Cash From Operating Activities	-$151.0K	$4.566M	$17.52M
YoY Change	-103.7%	23.04%	-4.36%
INVESTING ACTIVITIES
Capital Expenditures	$317.0K	$4.053M	$982.0K
YoY Change	78.09%	-163.29%	0.2%
Acquisitions
YoY Change
Other Investing Activities	$1.234M	$1.001M	$3.598M
YoY Change	27.74%	28.83%	-177.23%
Cash From Investing Activities	-$3.051M	-$3.052M	-$11.48M
YoY Change	42.37%	-45.76%	-46.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.459M
YoY Change			874.82%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.293M	-1.712M	-$6.060M
YoY Change	-291.9%	-188.38%	-6.24%
NET CHANGE
Cash From Operating Activities	-$151.0K	4.566M	$17.52M
Cash From Investing Activities	-$3.051M	-3.052M	-$11.48M
Cash From Financing Activities	$3.293M	-1.712M	-$6.060M
Net Change In Cash	$91.00K	-198.0K	-$21.00K
YoY Change	-58.45%	-1042.86%	-99.78%
FREE CASH FLOW
Cash From Operating Activities	-$151.0K	$4.566M	$17.52M
Capital Expenditures	$317.0K	$4.053M	$982.0K
Free Cash Flow	-$468.0K	$513.0K	$16.54M
YoY Change	-112.0%	-94.93%	-4.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15405000	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001337013
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	172308011	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20893018	shares
CY2022	dei	Auditor Firm AuditorFirmId	243
CY2022	dei	Auditor Name AuditorName	BDO USA, LLP
CY2022	dei	Auditor Location AuditorLocation	Troy, Michigan
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16871000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4821000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	3939000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2922000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2535000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	24779000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	22065000	usd
CY2022Q4	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	2790000	usd
CY2021Q4	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	1742000	usd
CY2022Q4	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	39450000	usd
CY2021Q4	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	39871000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4385000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4523000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3710000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3710000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8436000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10930000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4168000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4241000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	9625000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	10033000	usd
CY2022Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	1965000	usd
CY2021Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	355000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	80000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	116000	usd
CY2022Q4	us-gaap	Assets Assets	99388000	usd
CY2021Q4	us-gaap	Assets Assets	97586000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8341000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7862000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	349000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6126000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4685000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14467000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12896000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33157000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	32748000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3761000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3670000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	51385000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	49314000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20781977	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20781977	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20699546	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20699546	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105856000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101905000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1489000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	268000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59344000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53903000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48003000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48272000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	99388000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97586000	usd
CY2022	us-gaap	Revenues Revenues	109914000	usd
CY2021	us-gaap	Revenues Revenues	102382000	usd
CY2020	us-gaap	Revenues Revenues	97388000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	47343000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	42185000	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	38629000	usd
CY2022	us-gaap	Gross Profit GrossProfit	62571000	usd
CY2021	us-gaap	Gross Profit GrossProfit	60197000	usd
CY2020	us-gaap	Gross Profit GrossProfit	58759000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	87000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	77000	usd
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	791000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1239000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1688000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	17332000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	22334000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2610000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	190000	usd
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1714000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	17332000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	40752000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	812000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6404000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	348000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1172000	usd
CY2021	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	560000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	891000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3825000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	428000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1193000	usd
CY2022	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	5459000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1221000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48003000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1420000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	17332000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	87000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	77000	usd
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	791000	usd
CY2022	us-gaap	Depreciation Depreciation	10866000	usd
CY2021	us-gaap	Depreciation Depreciation	10363000	usd
CY2020	us-gaap	Depreciation Depreciation	9740000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1933000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1029000	usd
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	418000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2183000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2545000	usd
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	3577000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2494000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4262000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4285000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	73000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	151000	usd
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	17000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3825000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6404000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2610000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	19000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-153000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10071000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1153000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-829000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2631000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	882000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	864000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	102000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	387000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	133000	usd
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	740000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	135000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	161000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	186000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	2942000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-2363000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	2394000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17517000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18316000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20280000	usd
CY2022	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	usd
CY2021	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	7976000	usd
CY2020	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	usd
CY2022	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	14094000	usd
CY2021	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	15676000	usd
CY2020	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	15820000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	982000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	980000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1094000	usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	3598000	usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	3317000	usd
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	4752000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11478000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21315000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12162000	usd
CY2022	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	42035000	usd
CY2021	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	81660000	usd
CY2020	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	37180000	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	42022000	usd
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	76191000	usd
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	37587000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	386000	usd
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	750000	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5459000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	560000	usd
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1193000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1172000	usd
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1714000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1355000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1124000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6060000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9648000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1310000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1113000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1214000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	153000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	171000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	102000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1902000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1590000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	793000	usd
CY2022	infu	Noncash Or Part Noncash Acquisition Contingent Consideration Arrangements Change In Amount Of Contingent Consideration NoncashOrPartNoncashAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsideration	0	usd
CY2021	infu	Noncash Or Part Noncash Acquisition Contingent Consideration Arrangements Change In Amount Of Contingent Consideration NoncashOrPartNoncashAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsideration	750000	usd
CY2020	infu	Noncash Or Part Noncash Acquisition Contingent Consideration Arrangements Change In Amount Of Contingent Consideration NoncashOrPartNoncashAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsideration	0	usd
CY2022	infu	Noncash Activities Proceeds From Stock Plans NoncashActivitiesProceedsFromStockPlans	0	usd
CY2021	infu	Noncash Activities Proceeds From Stock Plans NoncashActivitiesProceedsFromStockPlans	36000	usd
CY2020	infu	Noncash Activities Proceeds From Stock Plans NoncashActivitiesProceedsFromStockPlans	0	usd
CY2022Q4	infu	Medical Equipment In Rental Service Net Of Accumulated Depreciation MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation	39450000	usd
CY2022	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation and Nature of Operations<div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">InfuSystem Holdings, Inc. and its consolidated subsidiaries (the “Company”) are a leading national provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from seven locations in the United States ("U.S.") and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. InfuSystem Inc. (“ISI”) and First Biomedical, Inc. ("First Biomedical") are both operating subsidiaries of the Company.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company’s pumps are electronic infusion pumps. Smiths Medical, Inc. and Moog Medical Devices Group each supplied more than 10% of the ambulatory pumps purchased by the Company in 2022. The Company has a supply agreement in place with each of these suppliers. Certain “spot” purchases are made on the open market subject to individual negotiation. The Company also supplies Negative Pressure Wound Therapy (“NPWT”) medical equipment, as well as related disposables and ancillary supplies.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing and acute care facilities, pain centers and others.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company’s ambulatory infusion pump management service.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).</span></div>
CY2022	infu	Number Of Locations NumberOfLocations	7	location
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	lease
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, leases, accounts receivable and allowance for doubtful accounts, income taxes, equity compensation valuations, and long-lived asset valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.</span></div>
CY2022Q4	infu	Medical Equipment Net MedicalEquipmentNet	42240000	usd
CY2022Q4	infu	Number Of Financial Institutions NumberOfFinancialInstitutions	2	financial_institution
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1100000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1100000	usd
CY2022	infu	Medical Equipment In Rental Services Useful Life MedicalEquipmentInRentalServicesUsefulLife	P7Y
CY2022Q4	infu	Medical Equipment In Rental Services Reserve MedicalEquipmentInRentalServicesReserve	2300000	usd
CY2021Q4	infu	Medical Equipment In Rental Services Reserve MedicalEquipmentInRentalServicesReserve	1100000	usd
CY2022	infu	Medical Equipment Increase In Pump Reserve MedicalEquipmentIncreaseInPumpReserve	400000	usd
CY2022	infu	Depreciation Expense Related To Medical Equipment DepreciationExpenseRelatedToMedicalEquipment	9800000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	0	usd
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	300000	usd
CY2022	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	100000	usd
CY2021	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1600000	usd
CY2020	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1900000	usd
CY2022	infu	Medical Equipment Increase In Pump Reserve MedicalEquipmentIncreaseInPumpReserve	400000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P9Y
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Concentration</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had contracts with nearly 800 third-party payer networks, an increase of 4% over the prior year period. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee </span></div>schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless the Company or the contracted payer elect not to renew. The Company also contracts with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of its Medicare patients and numerous other insurance carriers. No single payer or customer represented more than 10% of the Company's net revenue in 2022, 2021 or 2020.
CY2022Q4	infu	Number Of Contracts With Third Parties NumberOfContractsWithThirdParties	800	network
CY2022	infu	Percentage Increase In Number Of Contracts PercentageIncreaseInNumberOfContracts	0.04
CY2022	infu	Term Of Contract TermOfContract	P1Y
CY2022	infu	Term Of Renewal TermOfRenewal	P1Y
CY2021	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	3500000	shares
CY2022	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	0	shares
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	52572000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1420000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	17332000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20648818	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20519958	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20106940	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	898488	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1529701	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1610276	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21547306	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22049659	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21717216	shares
CY2022Q4	infu	Medical Equipment Held For Sale Or Rental MedicalEquipmentHeldForSaleOrRental	2790000	usd
CY2022Q4	infu	Medical Equipment In Rental Services Gross MedicalEquipmentInRentalServicesGross	99163000	usd
CY2022Q4	infu	Medical Equipment In Rental Services Reserve MedicalEquipmentInRentalServicesReserve	2270000	usd
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	7650000	usd
CY2021	infu	Working Capital WorkingCapital	325000	usd
CY2021	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	750000	usd
CY2021	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	8725000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	725000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	74000	usd
CY2021Q4	infu	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Medical Equipment Held For Sale Or Rental BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalEquipmentHeldForSaleOrRental	40000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	161000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	4015000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3710000	usd
CY2021Q4	infu	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right Of Use Asset BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset	288000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	288000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	8725000	usd
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	200000	usd
CY2021Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	4015000	usd
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y2M12D
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	103152000	usd
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	100032000	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	1936000	usd
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	16498000	usd
CY2022Q4	infu	Medical Equipment In Rental Services Accumulated Depreciation MedicalEquipmentInRentalServicesAccumulatedDepreciation	57443000	usd
CY2022	us-gaap	Revenues Revenues	109914000	usd
CY2021	us-gaap	Revenues Revenues	102382000	usd
CY2020	us-gaap	Revenues Revenues	97388000	usd
CY2022Q4	infu	Medical Equipment Held For Sale Or Rental Gross MedicalEquipmentHeldForSaleOrRentalGross	2802000	usd
CY2022Q4	infu	Medical Equipment For Sale Or Rental Reserve MedicalEquipmentForSaleOrRentalReserve	12000	usd
CY2021Q4	infu	Medical Equipment For Sale Or Rental Reserve MedicalEquipmentForSaleOrRentalReserve	46000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	2000000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	2000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	44136000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8436000	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	53802000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	42872000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10930000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2500000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4300000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	990000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	990000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	810000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	525000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	471000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2650000	usd
CY2022Q4	infu	Long Term Debt Gross Current LongTermDebtGrossCurrent	0	usd
CY2022Q4	infu	Long Term Debt Gross Noncurrent LongTermDebtGrossNoncurrent	33384000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33384000	usd
CY2021Q4	infu	Long Term Debt Gross Current LongTermDebtGrossCurrent	423000	usd
CY2021Q4	infu	Long Term Debt Gross Noncurrent LongTermDebtGrossNoncurrent	32974000	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33397000	usd
CY2022Q4	infu	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	0	usd
CY2022Q4	infu	Unamortized Debt Issuance Expense Noncurrent UnamortizedDebtIssuanceExpenseNoncurrent	227000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	227000	usd
CY2021Q4	infu	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	74000	usd
CY2021Q4	infu	Unamortized Debt Issuance Expense Noncurrent UnamortizedDebtIssuanceExpenseNoncurrent	226000	usd
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	300000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33157000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	33157000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	349000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	32748000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	33097000	usd
CY2022	us-gaap	Interest Expense InterestExpense	1400000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1400000	usd
CY2020	us-gaap	Interest Expense InterestExpense	1300000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	63000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1033000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	6623000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	67000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	224000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	920000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	130000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1257000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	7543000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	11000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-44000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-150000	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8346000	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-44000	usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-150000	usd
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-8335000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	99000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	167000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	66000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	65000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1725000	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	164000	usd
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	164000	usd
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-1659000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-8000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-177000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	205000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	112000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-163000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9789000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11250000	usd
CY2022	infu	Deferred Tax Assets Valuation Allowance Expense DeferredTaxAssetsValuationAllowanceExpense	0	usd
CY2021	infu	Deferred Tax Assets Valuation Allowance Expense DeferredTaxAssetsValuationAllowanceExpense	0	usd
CY2020	infu	Deferred Tax Assets Valuation Allowance Expense DeferredTaxAssetsValuationAllowanceExpense	0	usd
CY2022	infu	Deferred Tax Assets Valuation Allowance Increase DeferredTaxAssetsValuationAllowanceIncrease	0	usd
CY2021	infu	Deferred Tax Assets Valuation Allowance Increase DeferredTaxAssetsValuationAllowanceIncrease	0	usd
CY2020	infu	Deferred Tax Assets Valuation Allowance Increase DeferredTaxAssetsValuationAllowanceIncrease	0	usd
CY2022	infu	Deferred Tax Assets Valuation Allowance Release DeferredTaxAssetsValuationAllowanceRelease	0	usd
CY2021	infu	Deferred Tax Assets Valuation Allowance Release DeferredTaxAssetsValuationAllowanceRelease	0	usd
CY2020	infu	Deferred Tax Assets Valuation Allowance Release DeferredTaxAssetsValuationAllowanceRelease	11250000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	27000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	264000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1584000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	130000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	130000	usd
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	387000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	12000	usd
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	12000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	58000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-462000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-633000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-11250000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	79000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	34000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	0	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-28000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-73000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	111000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	112000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-163000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9789000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.860
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.129
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-1.298
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	9625000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	10033000	usd
CY2020Q4	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-11200000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1333000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1316000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1617000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	301000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	243000	usd
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	315000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1634000	usd
CY2021	us-gaap	Lease Cost LeaseCost	1559000	usd
CY2020	us-gaap	Lease Cost LeaseCost	1932000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1241000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1271000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1603000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	18000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	926000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	264000	usd
CY2022	infu	Increases To Right Of Use Assets Resulting From Lease Modifications IncreasesToRightOfUseAssetsResultingFromLeaseModifications	1050000	usd
CY2021	infu	Increases To Right Of Use Assets Resulting From Lease Modifications IncreasesToRightOfUseAssetsResultingFromLeaseModifications	0	usd
CY2020	infu	Increases To Right Of Use Assets Resulting From Lease Modifications IncreasesToRightOfUseAssetsResultingFromLeaseModifications	0	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.071
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1159000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1064000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1033000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	998000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	826000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2016000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7096000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2404000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4692000	usd
CY2022Q4	infu	Lessee Operating Lease Lease Not Yet Commenced Minimum Payment LesseeOperatingLeaseLeaseNotYetCommencedMinimumPayment	1800000	usd
CY2022Q4	us-gaap	Lessee Finance Lease Remaining Lease Term LesseeFinanceLeaseRemainingLeaseTerm	P7Y
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3800000	usd
CY2022	infu	Share Based Compensation Arrangement By Share Based Payment Award Options Reduction Ratio ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReductionRatio	1
CY2022	infu	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Reduction Ratio ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReductionRatio	2
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	2683000	usd
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense	4491000	usd
CY2020	us-gaap	Restricted Stock Expense RestrictedStockExpense	1687000	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1142000	usd
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1913000	usd
CY2020	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	923000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3825000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6404000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2610000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	857000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	2234000	usd
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1652000	usd
CY2022	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	136718	shares
CY2021	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	57067	shares
CY2020	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	146763	shares
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2022	us-gaap	Interest Expense InterestExpense	1402000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-122000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	112000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18000	usd
CY2022Q4	us-gaap	Assets Assets	99388000	usd
CY2022	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	14094000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13360000	usd
CY2021	infu	Revenues External RevenuesExternal	102382000	usd
CY2021	infu	Revenues Internal RevenuesInternal	0	usd
CY2021	us-gaap	Revenues Revenues	102382000	usd
CY2014Q2	us-gaap	Employee Stock Ownership Plan Esop Shares Contributed To Esop EmployeeStockOwnershipPlanESOPSharesContributedToESOP	200000	shares
CY2014Q2	infu	Employee Stock Purchase Plan Discount Rate EmployeeStockPurchasePlanDiscountRate	0.15
CY2014Q2	infu	Employee Stock Purchase Plan Offering Period EmployeeStockPurchasePlanOfferingPeriod	P6M
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	350000	shares
CY2014Q2	infu	Employee Stock Ownership Plan Espp Purchase Per Employee Maximum EmployeeStockOwnershipPlanESPPPurchasePerEmployeeMaximum	25000	usd
CY2022Q4	infu	Stock Issued During Period Shares Employee Stock Ownership Plan Number Of Remaining Shares Available For Future Issuance StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance	95379	shares
CY2022	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	229064	usd
CY2021	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	173561	usd
CY2020	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	108589	usd
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	60673	shares
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	31624	shares
CY2020	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	30012	shares
CY2022	infu	Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased	11.53
CY2021	infu	Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased	16.95
CY2020	infu	Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased	7.43
CY2021Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	20000000	usd
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	6000000.0	usd
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	531347	shares
CY2022	infu	Revenues External RevenuesExternal	109914000	usd
CY2022	infu	Revenues Internal RevenuesInternal	0	usd
CY2022	us-gaap	Revenues Revenues	109914000	usd
CY2022	us-gaap	Gross Profit GrossProfit	62571000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	60917000	usd
CY2021	us-gaap	Gross Profit GrossProfit	60197000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	57377000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1377000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-186000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-163000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	1420000	usd
CY2021Q4	us-gaap	Assets Assets	97586000	usd
CY2021	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	15676000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14625000	usd
CY2020	infu	Revenues External RevenuesExternal	97388000	usd
CY2020	infu	Revenues Internal RevenuesInternal	0	usd
CY2020	us-gaap	Revenues Revenues	97388000	usd
CY2020	us-gaap	Gross Profit GrossProfit	58759000	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	49932000	usd
CY2020	us-gaap	Interest Expense InterestExpense	1255000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-29000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9789000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	17332000	usd
CY2020Q4	us-gaap	Assets Assets	96991000	usd
CY2020	infu	Payments To Acquire Medical Equipment PaymentsToAcquireMedicalEquipment	15820000	usd
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14025000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1200000	usd
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	900000	usd
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	800000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3300000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1300000	usd

Files In Submission

Name	View Source	Status
0001628280-23-008290-index-headers.html	Edgar Link	pending
0001628280-23-008290-index.html	Edgar Link	pending
0001628280-23-008290.txt	Edgar Link	pending
0001628280-23-008290-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
infu-20221231.htm	Edgar Link	pending
infu-20221231.xsd	Edgar Link	pending
infu-20221231xexx2111.htm	Edgar Link	pending
infu-20221231xexx2311.htm	Edgar Link	pending
infu-20221231xexx3111.htm	Edgar Link	pending
infu-20221231xexx3121.htm	Edgar Link	pending
infu-20221231xexx3211.htm	Edgar Link	pending
infu-20221231xexx3221.htm	Edgar Link	pending
infu-20221231_g1.jpg	Edgar Link	pending
infu-20221231_g2.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
infu-20221231_cal.xml	Edgar Link	unprocessable
infu-20221231_def.xml	Edgar Link	unprocessable
infu-20221231_lab.xml	Edgar Link	unprocessable
infu-20221231_htm.xml	Edgar Link	completed
infu-20221231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INFU
InfuSystem Holdings, Inc Stock $infu

2023 Q1 Form 10-K Financial Statement

#000162828023008290 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INFU InfuSystem Holdings, Inc Stock $infu

2023 Q1 Form 10-K Financial Statement

#000162828023008290 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INFU
InfuSystem Holdings, Inc Stock $infu